LIDODERM (lidocaine patch 5%), is a topical therapy that works directly at the site of postherpetic neuralgia (PHN) pain and is backed by more than a decade of use. LIDODERM is the first and only lidocaine-based topical medication approved by the FDA for the treatment of pain associated with PHN, and offers you and your patients a custom fit for managing PHN pain.
A first-line therapy, alone or with oral analgesics
- Works directly at the site of pain
Proven efficacy in 2 randomized, placebo-controlled clinical trials (N=67)
- In the first study, patients felt significant pain relief at 30 minutes after the first dose vs observation cohort
- In the second study, 84% of PHN patients had moderate to complete pain relief at 2 weeks
- LIDODERM (lidocaine patch 5%) may take up to 2 weeks to achieve the best outcome
Efficacy of lidocaine patch 5% reaffirmed in a European clinical trial in PHN
- Patients remained on lidocaine patch 5% more than twice as long as placebo (median time to exit was 14 days vs 6 days; P=0.0398 per protocol population)
- Many PHN patients experienced clinically meaningful reductions in painful allodynia at the end of the run-in phase (week 8; n=71)
Demonstrated favorable safety profile and generally well tolerated
- No serious adverse events in clinical trials
- Low risk of drug-drug interactions; in clinical trials, patients used concomitant analgesics
- Use with caution in patients receiving Class 1 antiarrhythimics
Customized application for your patients with PHN pain
- A simple application in your office, or at home by your patients
- Patches can be cut to custom fit the areas of pain